Search results for "TISSUE"

showing 10 items of 4413 documents

Florid cemento-osseous dysplasia : report of 2 cases

2018

Introduction Florid cemento-osseous dysplasia is a non-neoplastic fibro-osseous lesion which often has an asymptomatic slow growth. Unfortunately, these lesions are usually diagnosed through routine radiographic examination. The aim of this study was to describe the main clinical, radiological and histological characteristics of two case reports diagnosed with florid cemento-osseous dysplasia. Case reports Two cases of florid cemento-osseous dysplasia with different clinical and radiological features were presented. Panoramic radiographs showed multiple radiopacities compatible with fibro-osseous lesions in distinct areas of the maxillary bones. The histological study revealed a sclerotic m…

musculoskeletal diseasesmedicine.medical_specialtyRadiographyCase ReportFibrous tissueMaxillary BonesAsymptomaticLesion03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineOssosDisplàsia fibrosa òssia030223 otorhinolaryngologyGeneral DentistryOral Medicine and PathologyBonesbusiness.industry030206 dentistryFlorid cemento-osseous dysplasiamusculoskeletal systemmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Fibrous dysplasia of bonestomatognathic diseasesEstudi de casosDysplasiaUNESCO::CIENCIAS MÉDICASRadiologyCase studiesmedicine.symptombusinessGigantiform cementoma
researchProduct

The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice.

2015

The new 2010 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) criteria of Rheumatoid Arthritis recently published, have been released to classify and identify patients with early RA who could benefit from early therapy. They recommend anti-citrullinated protein antibody (ACPA) testing as an alternative criterion to Rheumatoid Factor (RF) and ACPA that were introduced together with the other classic criteria in a scoring system. We previously criticized these new criteria because of unavailable specificity and sensibility in the first paper, and the use of ACPA as dichotomous criterion (presence/absent) and alternatives to rheumatoid factor. Our previous work p…

musculoskeletal diseasesmedicine.medical_specialtyScoring systemEarly rheumatoid arthritiEarly TherapyPeptides CyclicSensitivity and SpecificityAntibodiesArthritis RheumatoidInternal medicineInternal MedicineMedicineRheumatoid factorHumansACR/EULAR criteriaskin and connective tissue diseasesIntensive care medicineSocieties Medicalbusiness.industryProbabilistic logicmedicine.diseaseLikelihood ratioRheumatologyACR criteriaClinical PracticeEarly DiagnosisRheumatoid arthritisPractice Guidelines as TopicPhysical therapyEmergency MedicineProbabilistic clinical reasoningbusinessRheumatismInternal and emergency medicine
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct

Die Kleinfragment-Doppelplattenosteosynthese bei C1- bis C3-Frakturen des Pilon tibiale

2008

Intra-articular fractures of the tibial pilon always have been a challenge for the surgeon and his operative technique. With conservative or operative management, we have to take care of destroyed articular surfaces and traumatised soft tissues. Therefore, tibial pilon fractures are known in the literature as complicated lesions with a high rate of complications. Between 1993 and 2001 twenty-one patients who were between 18 and 65 years old and suffered a monotrauma of the tibial pilon of the type C1 to C3 of the AO classification, were treated with a staged reconstruction. Stabilisation was done by small-fragment double plate osteosynthesis. In this retrospective study, we could review 17 …

musculoskeletal diseasesmedicine.medical_specialtybusiness.industrySoft tissueRetrospective cohort studyOsteoarthritismedicine.diseaseSurgerymedicine.anatomical_structurePlate osteosynthesisRadiological weaponBone platemedicineOrthopedics and Sports MedicineSurgeryTibial pilonAnklebusinessZeitschrift für Orthopädie und Unfallchirurgie
researchProduct

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

2021

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of rheumatology
researchProduct

Distal Humerus Fractures

2014

Distal humerus fractures display seldom but severe injuries because of the complex distal humerus anatomy and often comminuted fracture types. They account for approximately 2–3 % of all fractures and for 17–30 % of fractures around the elbow. In younger patients, there is a predominance among males. The mechanism of accident is mostly a high-energy trauma in this population. In contrast, among elderly patients, distal humerus fractures concern mostly women with osteoporotic bone. Fractures are caused by a low-energy trauma such as a fall from standing height onto the outstretched or slightly flexed arm. These fractures are often severely comminuted. Because of the thin soft tissue envelope…

musculoskeletal diseasesmedicine.medical_specialtyeducation.field_of_studybusiness.industryElbowPopulationDistal humerusSoft tissueAnatomymusculoskeletal systemmedicine.diseaseSurgerymedicine.anatomical_structuremedicine.arterymedicineOsteoporotic boneHeterotopic ossificationBrachial arteryeducationbusinessFracture type
researchProduct

Celecoxib for recurrent sclerouveitis after syphilitic panuveitis. A case report

2011

Purpose To report a case of recurrent ocular inflammation after optimal therapy of bilateral syphilitic panuveitis responding to oral celecoxib. Methods A case report was conducted. Results A 76-year-old man presented with painful blurry vision in both eyes. Ocular examination disclosed bilateral panuveitis. Serological testing confirmed blood and cerebrospinal fluid syphilitic involvement. After 2 weeks of intravenous penicillin therapy, recurrent episodic sclerouveitis was observed. Conclusion Ocular inflammation after healing of infectious uveitis is a rare ophthalmic sequela. In an immunocompetent patient, either re-infection or immune uveitis should be evoked. Non-steroidal therapeutic…

musculoskeletal diseasesmedicine.medical_specialtygenetic structuresbusiness.industryBrief ReportPanuveitisSclerouveitisDermatologyeye diseasesOphthalmologyInfectious DiseasesCelecoxibBilateral syphilitic panuveitisCelecoxibmedicinelipids (amino acids peptides and proteins)heterocyclic compoundsTreponema pallidumskin and connective tissue diseasesbusinessOcular inflammationmedicine.drugJournal of Ophthalmic Inflammation and Infection
researchProduct

Upper Limb Interventions.

2019

Ultrasound has been reported to be a quick, cheap, and effective imaging modality to guide the interventional procedures in the musculoskeletal system. The use of ultrasound results in increased accuracy of needle placement associated with a reduction of complications. In the upper limb, ultrasound-guided procedures are applied to joints and soft tissues around the shoulder, elbow, wrist, and hand. This article reviews the clinical and technical aspects of the most common procedures performed in this anatomic area.

musculoskeletal diseasesmedicine.medical_specialtymedicine.medical_treatmentElbowPsychological interventionWrist030218 nuclear medicine & medical imagingUpper Extremity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationMedicineHumansRadiology Nuclear Medicine and imagingReduction (orthopedic surgery)Ultrasonography Interventionalmedicine.diagnostic_testbusiness.industryUltrasoundSoft tissueInterventional radiologyGeneral Medicinemedicine.anatomical_structure030220 oncology & carcinogenesisTendinopathyUpper limbbusinessRadiologic clinics of North America
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct